Achieving osteoporosis treat-to-target goals with teriparatide or alendronate: sub-analysis of Japanese Osteoporosis Intervention Trial-05 (JOINT-05)
Journal of Bone and Mineral Metabolism · 2024
DOI: 10.1007/s00774-024-01515-5 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Bone and Mineral Metabolism, 2024. Verfasst von Hiroshi Hagino und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rehabilitation, Sanin Rosai Hospital, 1-8-1 Kaikeshinden, Yonago, Tottori, 683-8605, Japan. hagino@tottori-u.ac.jp. Hauptthemen laut MEDLINE: Alendronate, Teriparatide, Bone Density. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Public Health Research Foundation, Asahi Kasei Pharma Corp..
Abstract (Originalsprache)
Introduction
The purpose of this study was to evaluate whether bone mineral density (BMD) ≥ −2.5 SD could be used as the treat-to-target (T2T) goal when treating osteoporosis with teriparatide (TPTD) and alendronate (ALN), and to investigate the relationship with incident vertebral fracture by re-analyzing data from a randomized, controlled trial (JOINT-05) involving postmenopausal Japanese women at high fracture risk. Materials and methods Participants received sequential therapy with once-weekly TPTD for 72 weeks, followed by ALN for 48 weeks (TPTD-ALN group) or ALN monotherapy for 120 weeks (ALN group). BMDs were measured at the lumbar spine (L2-4), total hip, and femoral neck at 0, 24, 48, 72, and 120 weeks by dual-energy X-ray absorptiometry. The T2T goal was BMD ≥ −2.5 SD, and the endpoint was the proportion of participants with baseline BMD < −2.5 SD in three measurement sites achieving BMD ≥ −2.5 SD.
Results
A total of 559 participants were selected. BMD ≥ −2.5 SD at 120 weeks in the L2-4, total hip, and femoral neck sites was achieved in 20.5%, 23.1%, and 5.9%, respectively, in the TPTD-ALN group and 22.2%, 11.7%, and 7.3%, respectively, in the ALN group. Incident vertebral fractures occurred in areas of both lower and high BMD.
Conclusion
During the 1.5-year treatment period, more than 20% of participants achieved BMD ≥ −2.5 SD as a T2T goal at L2-4. Since the achievement level differed depending on the BMD measurement site, the appropriate site should be selected according to the baseline BMD level.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rehabilitation, Sanin Rosai Hospital, 1-8-1 Kaikeshinden, Yonago, Tottori, 683-8605, Japan. hagino@tottori-u.ac.jp.
- Department of Clinical Biostatistics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
- Public Health Research Foundation, Shinjuku-Ku, Tokyo, Japan.
- Seirei Hamamatsu General Hospital, Hamamatsu, Japan.
- Soen Orthopaedics, Osteoporosis and Rheumatology Clinic, Kobe, Hyogo, Japan.
Förderung
- Public Health Research Foundation
- Asahi Kasei Pharma Corp.
Zitieren
APA
Hagino, H., Tanaka, S., Kuroda, T., Mori, S., & Soen, S. (2024). Achieving osteoporosis treat-to-target goals with teriparatide or alendronate: sub-analysis of Japanese Osteoporosis Intervention Trial-05 (JOINT-05). Journal of Bone and Mineral Metabolism. https://doi.org/10.1007/s00774-024-01515-5
Vancouver
Hagino H, Tanaka S, Kuroda T, Mori S, Soen S. Achieving osteoporosis treat-to-target goals with teriparatide or alendronate: sub-analysis of Japanese Osteoporosis Intervention Trial-05 (JOINT-05). Journal of Bone and Mineral Metabolism. 2024. doi:10.1007/s00774-024-01515-5
BibTeX
@article{Hagino2024,
author = {Hagino, Hiroshi and Tanaka, Shiro and Kuroda, Tatsuhiko and Mori, Satoshi and Soen, Satoshi},
title = {Achieving osteoporosis treat-to-target goals with teriparatide or alendronate: sub-analysis of Japanese Osteoporosis Intervention Trial-05 (JOINT-05)},
journal = {Journal of Bone and Mineral Metabolism},
year = {2024},
doi = {10.1007/s00774-024-01515-5}
}
EUVIMED